文献速递核素与放射性配体治疗肿瘤 PET/CT

核医学与华尔街:不断演变的关系

Nuclear Medicine and Wall Street: An Evolving Relationship.
PubMed 文献 · J Nucl Med · 2019-01-01

本文讨论华尔街和大型制药公司对放射性药物机会的态度转变。多数诊断性放射性药物经济前景有限,未能吸引广泛商业兴趣,但靶向放射性配体治疗领域的少数显著成功正改变这一局面,推动投资者资本流入并加剧并购活动。若核医学行业能继续有效管理历史挑战,放射性配体治疗有望改变肿瘤治疗范式并提升整个核医学板块的地位。

要点

  • 诊断性放射性药物经济前景有限,历史上难以吸引华尔街和大型药企兴趣。
  • 靶向放射性配体治疗的少数成功案例正改变投资动态,带来资本流入与并购活跃。
  • 行业若继续有效管理历史挑战,放射性配体治疗有望改变肿瘤治疗范式。

核心结论

  • 靶向放射性配体治疗领域的少数显著成功正改变华尔街和大型药企对放射性药物的态度,推动资本流入和并购活动。
  • 若核医学行业能继续有效管理历史挑战,放射性配体治疗有望显著改变肿瘤治疗范式并提升整个核医学板块的地位。

主要发现

  • 多数诊断性放射性药物经济前景有限,尽管诊断成像能力快速进步且在治疗过程中作用日益关键,仍未吸引广泛商业界的浓厚兴趣。
  • 支持特定放射性药物治疗肿瘤的有力科学被这类药物的独特挑战和历史商业失败所掩盖。
  • 靶向放射性配体治疗领域的少数显著成功正推动投资者资本新流入这些技术,并加剧并购活动,为投资者创造显著价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Until recently, it has been challenging to engage Wall Street and large pharmaceutical companies in radiopharmaceutical opportunities. The modest economic prospects of most diagnostic radiopharmaceuticals have not attracted keen interest from the broader business community, despite the rapid advancement of diagnostic imaging capabilities and their increasingly crucial role in the therapeutic process. Similarly, compelling science supporting select radiopharmaceutical therapies in oncology has been overshadowed by the unique challenges posed by this class of drugs and historical commercial failures that serve as sobering reminders of risk. Fortunately, a few notable successes in the targeted radioligand therapeutic space are changing this dynamic, fueling a new flow of investor capital into these technologies and inciting increased merger and acquisition activity that has yielded significant value creation for investors. If the nuclear medicine industry is able to continue to effectively manage historical challenges, then there is significant opportunity for a new and promising wave of radioligand therapies to significantly change the oncology treatment paradigm and elevate the profile of the entire nuclear medicine sector.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sherman M, Levine R. Nuclear Medicine and Wall Street: An Evolving Relationship. J Nucl Med. 2019. PMID: 31481585. doi:10.2967/jnumed.118.220798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。